NO991483L - Insulin C-peptider - Google Patents
Insulin C-peptiderInfo
- Publication number
- NO991483L NO991483L NO991483A NO991483A NO991483L NO 991483 L NO991483 L NO 991483L NO 991483 A NO991483 A NO 991483A NO 991483 A NO991483 A NO 991483A NO 991483 L NO991483 L NO 991483L
- Authority
- NO
- Norway
- Prior art keywords
- peptide
- fragment
- peptides
- atpase activity
- stimulate
- Prior art date
Links
- 108010075254 C-Peptide Proteins 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 108091006112 ATPases Proteins 0.000 abstract 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 208000002249 Diabetes Complications Diseases 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 230000003592 biomimetic effect Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 108010038088 glutamyl-glycyl-seryl-leucyl-glutamine Proteins 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 150000002894 organic compounds Chemical class 0.000 abstract 1
- 210000005233 tubule cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9603533A SE520392C2 (sv) | 1996-09-27 | 1996-09-27 | Specifika peptider för behandling av diabetes mellitus |
| PCT/GB1997/002627 WO1998013384A1 (en) | 1996-09-27 | 1997-09-26 | Insulin c-peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO991483D0 NO991483D0 (no) | 1999-03-26 |
| NO991483L true NO991483L (no) | 1999-05-18 |
Family
ID=20404052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO991483A NO991483L (no) | 1996-09-27 | 1999-03-26 | Insulin C-peptider |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6610649B2 (de) |
| EP (1) | EP0938503B1 (de) |
| JP (1) | JP2001500893A (de) |
| KR (1) | KR20000048643A (de) |
| AT (1) | ATE347562T1 (de) |
| AU (1) | AU741901B2 (de) |
| BG (1) | BG103362A (de) |
| BR (1) | BR9711573A (de) |
| CA (1) | CA2266416C (de) |
| CZ (1) | CZ108599A3 (de) |
| DE (1) | DE69737065T2 (de) |
| DK (1) | DK0938503T3 (de) |
| ES (1) | ES2278394T3 (de) |
| HU (1) | HUP0000432A3 (de) |
| IL (1) | IL129143A0 (de) |
| IS (1) | IS5008A (de) |
| NO (1) | NO991483L (de) |
| NZ (1) | NZ335231A (de) |
| PL (1) | PL332494A1 (de) |
| RU (1) | RU2206336C2 (de) |
| SE (1) | SE520392C2 (de) |
| SK (1) | SK39499A3 (de) |
| TR (1) | TR199900694T2 (de) |
| WO (1) | WO1998013384A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0022342D0 (en) | 2000-09-12 | 2000-10-25 | Creative Peptides Sweden Ab | Reduction of the electrocardiographic QT interval |
| DE10055857A1 (de) * | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
| US20030198666A1 (en) * | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| AU2004204727B8 (en) * | 2003-01-06 | 2006-11-09 | Emisphere Technologies, Inc. | Night-time oral insulin therapy |
| US20050026826A1 (en) * | 2003-01-17 | 2005-02-03 | Margarethe Hoenig | Feline proinsulin, insulin and constituent peptides |
| US20050203001A1 (en) * | 2004-03-05 | 2005-09-15 | Emisphere Technologies, Inc. | Oral insulin therapies and protocol |
| GB0323979D0 (en) | 2003-10-13 | 2003-11-19 | Creative Peptides Sweden Ab | Therapeutic applications for c-peptide |
| WO2005117937A2 (en) * | 2004-05-27 | 2005-12-15 | Essential Skincare Llc | Alpha-1- acid glycoprotein for the treatment of diabetes |
| US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
| GB0601950D0 (en) * | 2006-01-31 | 2006-03-15 | Creative Peptides Sweden Ab | Compositions and methods of treating diabetes |
| EP2054437A2 (de) * | 2006-08-07 | 2009-05-06 | Teva Biopharmaceuticals USA, Inc. | Albumin-insulin-fusionsproteine |
| WO2009046847A2 (en) * | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Use of peptide ll-37 as a therapeutic agent |
| GB0723250D0 (en) * | 2007-11-28 | 2008-01-09 | Univ Leeds | Compositions and methods for reducing macrovascular complications in diabetic patients |
| WO2010033207A1 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
| US20110165112A1 (en) * | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of c-peptides |
| US8410049B2 (en) * | 2009-10-28 | 2013-04-02 | Cebix | Methods and kits for preventing hypoglycemia |
| NZ603399A (en) | 2010-05-17 | 2014-09-26 | Cebix Inc | Pegylated c-peptide |
| EP2683393B1 (de) | 2011-02-11 | 2018-04-11 | The Regents of The University of Michigan | Tripeptidzusammensetzungen und deren verwendung zur behandlung von diabetes |
| EP2780030A4 (de) | 2011-11-17 | 2015-11-18 | Cebix Ab | Pegyliertes c-peptid |
| RU2522897C1 (ru) * | 2013-04-16 | 2014-07-20 | Закрытое акционерное общество "ФАРМ-ХОЛДИНГ" | Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты) |
| KR101676542B1 (ko) * | 2014-12-30 | 2016-11-16 | 건국대학교 산학협력단 | 프로인슐린의 면역학적 용도 |
| CN104888201B (zh) * | 2015-06-29 | 2018-04-27 | 齐锦生 | 用于防治糖尿病及其慢性并发症的肽类药物 |
| SG11201906939XA (en) | 2017-02-06 | 2019-08-27 | Resiliun B V | Interaction between c-peptides and elastin receptor, a model for understanding vascular disease |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU166913B (de) * | 1972-05-15 | 1975-06-28 | ||
| JPS5210872B2 (de) | 1973-07-14 | 1977-03-26 | ||
| JPS55105653A (en) * | 1978-10-02 | 1980-08-13 | Shionogi & Co Ltd | Tyrosyl c-peptides |
| IL66611A0 (en) | 1981-08-27 | 1982-12-31 | Lilly Co Eli | Pharmaceutical formulations comprising human insulin and human c-peptide |
| DE3326473A1 (de) | 1983-07-22 | 1985-01-31 | Hoechst Ag, 6230 Frankfurt | Pharmazeutisches mittel zur behandlung des diabetes mellitus |
| US4581165A (en) * | 1984-06-14 | 1986-04-08 | Eli Lilly And Company | Anti-diabetic compounds |
| US5104854A (en) | 1989-02-01 | 1992-04-14 | Washington University | Antiviral peptides |
| NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
| US5364757A (en) | 1990-05-21 | 1994-11-15 | Administrators Of The Tulane Educational Fund | Methods of supporting a diagnosis of systemic lupus erythematosus |
| IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| JPH05268982A (ja) | 1992-03-27 | 1993-10-19 | Hoechst Japan Ltd | 骨形成作用を有する新規な蛋白質およびその製造法 |
| DK0640101T3 (da) | 1992-04-13 | 2000-05-15 | Oklahoma Med Res Found | Fremgangsmåder og reagenser til diagnosticering af autoantistoffer |
| WO1994025071A1 (en) | 1993-05-05 | 1994-11-10 | Keith Rose | Polyoxime compounds and their preparation |
| AT400723B (de) | 1993-08-27 | 1996-03-25 | Biomay Prod & Handel | Rekombinante alternaria alternata allergene |
| ES2130629T3 (es) | 1994-07-08 | 1999-07-01 | Dartmouth College | Compuestos peptidicos de proinsulina para detectar y tratar la diabetes tipo i. |
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| GB9422175D0 (en) | 1994-11-03 | 1994-12-21 | Univ Dundee | Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof |
| GB9509164D0 (en) | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
| CA2249742A1 (en) | 1996-03-15 | 1997-09-18 | Steven G. Reed | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
| US6150500A (en) | 1996-07-12 | 2000-11-21 | Salerno; John C. | Activators of endothelial nitric oxide synthase |
-
1996
- 1996-09-27 SE SE9603533A patent/SE520392C2/sv not_active IP Right Cessation
-
1997
- 1997-09-26 TR TR1999/00694T patent/TR199900694T2/xx unknown
- 1997-09-26 JP JP10515410A patent/JP2001500893A/ja not_active Ceased
- 1997-09-26 CZ CZ991085A patent/CZ108599A3/cs unknown
- 1997-09-26 HU HU0000432A patent/HUP0000432A3/hu unknown
- 1997-09-26 NZ NZ335231A patent/NZ335231A/xx unknown
- 1997-09-26 DK DK97942119T patent/DK0938503T3/da active
- 1997-09-26 AT AT97942119T patent/ATE347562T1/de not_active IP Right Cessation
- 1997-09-26 ES ES97942119T patent/ES2278394T3/es not_active Expired - Lifetime
- 1997-09-26 EP EP97942119A patent/EP0938503B1/de not_active Expired - Lifetime
- 1997-09-26 IL IL12914397A patent/IL129143A0/xx unknown
- 1997-09-26 WO PCT/GB1997/002627 patent/WO1998013384A1/en active IP Right Grant
- 1997-09-26 US US09/269,439 patent/US6610649B2/en not_active Expired - Fee Related
- 1997-09-26 DE DE69737065T patent/DE69737065T2/de not_active Expired - Lifetime
- 1997-09-26 RU RU99108434/14A patent/RU2206336C2/ru not_active IP Right Cessation
- 1997-09-26 CA CA002266416A patent/CA2266416C/en not_active Expired - Fee Related
- 1997-09-26 AU AU43915/97A patent/AU741901B2/en not_active Ceased
- 1997-09-26 PL PL97332494A patent/PL332494A1/xx unknown
- 1997-09-26 BR BR9711573-8A patent/BR9711573A/pt not_active Application Discontinuation
- 1997-09-26 KR KR1019990702585A patent/KR20000048643A/ko not_active Application Discontinuation
- 1997-09-26 SK SK394-99A patent/SK39499A3/sk unknown
-
1999
- 1999-03-23 IS IS5008A patent/IS5008A/is unknown
- 1999-03-26 NO NO991483A patent/NO991483L/no not_active Application Discontinuation
- 1999-04-27 BG BG103362A patent/BG103362A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BG103362A (en) | 2000-05-31 |
| BR9711573A (pt) | 2000-01-18 |
| IL129143A0 (en) | 2000-02-17 |
| ATE347562T1 (de) | 2006-12-15 |
| PL332494A1 (en) | 1999-09-13 |
| HUP0000432A3 (en) | 2000-10-30 |
| SE520392C2 (sv) | 2003-07-01 |
| IS5008A (is) | 1999-03-23 |
| DE69737065T2 (de) | 2007-06-28 |
| SK39499A3 (en) | 1999-10-08 |
| US20020107175A1 (en) | 2002-08-08 |
| ES2278394T3 (es) | 2007-08-01 |
| WO1998013384A1 (en) | 1998-04-02 |
| RU2206336C2 (ru) | 2003-06-20 |
| AU741901B2 (en) | 2001-12-13 |
| JP2001500893A (ja) | 2001-01-23 |
| EP0938503A1 (de) | 1999-09-01 |
| DK0938503T3 (da) | 2007-04-10 |
| NZ335231A (en) | 2000-11-24 |
| SE9603533D0 (sv) | 1996-09-27 |
| TR199900694T2 (xx) | 1999-06-21 |
| CZ108599A3 (cs) | 1999-08-11 |
| NO991483D0 (no) | 1999-03-26 |
| SE9603533L (sv) | 1998-03-28 |
| CA2266416C (en) | 2008-04-29 |
| DE69737065D1 (en) | 2007-01-18 |
| AU4391597A (en) | 1998-04-17 |
| KR20000048643A (ko) | 2000-07-25 |
| US6610649B2 (en) | 2003-08-26 |
| EP0938503B1 (de) | 2006-12-06 |
| CA2266416A1 (en) | 1998-04-02 |
| HUP0000432A2 (hu) | 2000-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO991483L (no) | Insulin C-peptider | |
| Wagstaff et al. | Molecular characterisation of endogenous snake venom metalloproteinase inhibitors | |
| PT93910A (pt) | Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula | |
| GB9519275D0 (en) | Substances and their therapeutic use | |
| ATE497390T1 (de) | Neue therapeutische verwendung von smr-1 peptide | |
| GB9422175D0 (en) | Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof | |
| EP0981352A4 (de) | Verfahren zur eosinophilveringerung und zusammensetzungen dafür | |
| NO974260L (no) | Nye definerte enzymblandinger for oppnåelse av celler og behandling av sår | |
| FI971427A (fi) | Peptidit ja niitä sisältävät farmaseuttiset koostumukset | |
| NO933742L (no) | Humant, benavledet, insulinlignende vekstfaktorbindingsprotein | |
| DE69712182T2 (de) | Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises | |
| WO1997040073A3 (de) | BIOLOGISCH AKTIVER EIWEISSSTOFF - KOLLAGENFRAGMENT HF-COLL-18/514cf - ZUR HEMMUNG DES WACHSTUMS VON TUMOREN UND VON GEFÄSSWUCHERUNGEN | |
| BR0308040A (pt) | Composições farmacêuticas e cosméticas compreendendo plgf-1 | |
| EP1598420A3 (de) | Pharmazeutische Zusammensetzungen und deren Verwendung insbesondere in der Behandlung von neurodegenerativen Krankheiten | |
| Sobolewski et al. | Binding of the basic fibroblast growth factor (bFGF) by soluble components of human umbilical cord. | |
| NO20023914D0 (no) | Preparater for anvendelse ved regulering av Parkin- genaktiviteten | |
| DK1340507T3 (da) | Anvendelse af et fibroblastvækstfaktor-bindingsprotein til behandling og diagnosticering af diabetiske sårhelingsforstyrrelser | |
| WO2005005668A3 (en) | Diagnosis and treatment methods related to aging (8a) | |
| WO2002062996A1 (fr) | Nouveau peptide physiologiquement actif et utilisation de ce peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |